Canaccord analyst Whitney Ijem initiated coverage of Arcturus Therapeutics with a Buy rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARCT:
- Arcturus Therapeutics price target raised to $60 from $51 at H.C. Wainwright
- CSL’s and Arcturus Therapeutics’ mRNA vaccine for COVID approved in Japan
- Arcturus Therapeutics receives Orphan Drug Designation for ARCT-032 from FDA
- Arcturus Therapeutics treatment of cystic fibrosis granted orphan status
- Biotech Alert: Searches spiking for these stocks today
